Novartis (NVS) to Release Earnings on Friday

Novartis (NYSE:NVS) is expected to be posting its quarterly earnings results before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12.86 billion for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The company had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same period in the previous year, the company posted $1.74 EPS. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Stock Performance

Shares of NVS opened at $101.85 on Wednesday. The stock has a 50-day simple moving average of $100.10 and a 200-day simple moving average of $108.64. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The stock has a market capitalization of $208.19 billion, a PE ratio of 11.83, a PEG ratio of 1.42 and a beta of 0.57. Novartis has a 1 year low of $92.35 and a 1 year high of $120.92.

Analyst Upgrades and Downgrades

NVS has been the subject of several recent research reports. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets boosted their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.